One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Alcohol-related harms and the case for minimum unit pricing
doi : 10.1016/S2468-1253(21)00229-6
Volume 6, Issue 8, August 2021, Page 597
Are we ready for patient-reported outcomes in hepatocellular carcinoma?
NicolaPersoneniaLorenzaRimassaa
Diversity in clinical trials: an opportunity and imperative for community engagement
Darrell MGrayIIabTimiya SNolanbcJohnGregorydJoshua JJosepha
Double trouble: a pandemic of obesity and COVID-19
Santosh KumarK YaPraveen KumarR BhataChandrashekar JSorakeb
Pooling samples for hepatitis C RNA detection
AntonioAguileraabcSaraPereiraaAnaFuentesdAdolfode SalazardRocÃoTrastoyaDanielNavarroaCamila APicchioeJeffrey VLazaruseFedericoGarcÃadf
Management of gastrointestinal services in Tamil Nadu, India, during COVID-19
ArulrajRamakrishnanabAravindhSomasundaramaNandhakumarSrinivasancSibithooranKarmeganbSnehaMadavbKrishnaveniRamasamybNagaselvapandiBalasubramanibSivakumarVenkatachalamdJeevithanShanmugamePaariVijayaragavanbRameshArasaradnamf
Urgent action needed to eliminate viral hepatitis by 2030
UdaniSamarasekera
6th World Congress of Paediatric Gastroenterology, Hepatology and Nutrition
SheilaPinion
In the light of evolutionJeremy Woodward, The Gastro-Archeologist, Springer (2021), p. 321, £21·99, ISBN: 978-3030626204
JenniferThorley
Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial
ProfArndtVogelMDaProfShukuiQinMDbProfMasatoshiKudoMDcYunSuMDdStacieHudgensMSceTatsuyaYamashitaMDfJung-HwanYoonMDgLaetitiaFartouxMDhKrzysztofSimonMDiCarlosLópezPhDjMaxSungMDkKalgiModyMDdTatsurohOhtsukaMSdToshiyukiTamaiMSdLeeBennettMSlGenevieveMeierDphardValeryBrederDrMedScim
Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination
OsmanÖcalMDaStephanie-SusanneStecherMDbProfMoritzWildgruberMDa
